These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31829065)

  • 1. Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications.
    Kalemeera F; Godman B; Stergachis A; Rennie T
    Hosp Pract (1995); 2020 Feb; 48(1):35-40. PubMed ID: 31829065
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of tenofovir containing ART on renal function in patients with moderate/severe reduced creatinine clearance at baseline: A retrospective study at two referral hospitals in Namibia.
    Kalemeera F; Godman B; Stergachis A; Rennie T
    Pharmacol Res Perspect; 2023 Feb; 11(1):e00681. PubMed ID: 36585791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function.
    Estébanez M; Bernardino JI; Serrano L; Pérez-Valero I; Zamora FX; Montes-Ramírez ML; González-García JJ; Arribas JR
    Enferm Infecc Microbiol Clin; 2016 Jan; 34(1):29-32. PubMed ID: 25735716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversibility of renal dysfunction after discontinuation of tenofovir.
    Cha A; Besignano-Long AR; Rothberger N; Shah B
    J Am Pharm Assoc (2003); 2016; 56(3):280-3. PubMed ID: 27067552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
    Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
    PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
    Yilma D; Abdissa A; Kæstel P; Tesfaye M; Olsen MF; Girma T; Ritz C; Friis H; Andersen ÅB; Kirk O
    BMC Infect Dis; 2020 Aug; 20(1):582. PubMed ID: 32762646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
    Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
    Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
    J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
    Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
    Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
    Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
    J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal changes in renal glomerular function associated with the use of Tenofovir Disoproxil Fumarate in HIV-infected Nigerians.
    Agbaji OO; Agaba PA; Idoko JA; Taiwo B; Murphy R; Kanki P; Ekong E
    West Afr J Med; 2011; 30(3):164-8. PubMed ID: 22120479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia.
    Kalemeera F; Mbango C; Mubita M; Naikaku E; Gaida R; Godman B
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):777-83. PubMed ID: 27309846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of tenofovir due to nephrotoxicity: insight into 12 years of clinical practice.
    Matłosz B; Kowalska JD; Bąkowska E; Firląg-Burkacka E; Vassilenko A; Horban A
    Przegl Epidemiol; 2019; 73(2):249-255. PubMed ID: 31385682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
    Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.
    Salome T; Kasamba I; Mayanja BN; Kazooba P; Were J; Kaleebu P; Munderi P;
    AIDS Res Ther; 2016; 13(1):28. PubMed ID: 27582777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana.
    Nartey ET; Tetteh RA; Yankey BA; Mantel-Teeuwisse AK; Leufkens HGM; Dodoo ANO; Lartey M
    BMC Res Notes; 2019 Jul; 12(1):445. PubMed ID: 31331365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea.
    Lee JE; Lee S; Song SH; Kwak IS; Lee SH
    Korean J Intern Med; 2019 Mar; 34(2):409-417. PubMed ID: 29020764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar.
    Kyaw NT; Harries AD; Chinnakali P; Antierens A; Soe KP; Woodman M; Das M; Shetty S; Zuu MK; Htwe PS; Fernandez M
    PLoS One; 2015; 10(8):e0135188. PubMed ID: 26301416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial.
    Baltrusaitis K; Makanani B; Tierney C; Fowler MG; Moodley D; Theron G; Nyakudya LH; Tomu M; Fairlie L; George K; Heckman B; Knowles K; Browning R; Siberry GK; Taha TE; Stranix-Chibanda L;
    BMC Infect Dis; 2022 Jul; 22(1):634. PubMed ID: 35858874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort.
    Monteiro N; Branco M; Peres S; Borges F; Mansinho K
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19565. PubMed ID: 25394072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.